[1] 刘宁,王玖.急性心肌梗死患者预后影响因素分析[J].中国疗养医学,2014, 23(12):1072-1075.
[2] 黄金和.急性心肌梗死的药物治疗新进展[J].中国民族民间医药,2012,21(1):10-11.
[3] Csonka C, Kupai K, Kocsis GF, et al. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010;61(2):163-170.
[4] 荣彦生,刘义,于晗.舒芬太尼后处理对大鼠心肌缺血再灌注损伤保护作用的实验研究[J].中西医结合心血脑血管病杂志, 2011, 9(10):1228-1230.
[5] 何志裕,陆东风.人脐带血间充质干细胞移植对急性心肌梗死大鼠心功能的影响[J].血栓与止血学, 2010, 16(6): 244-249.
[6] 马会利,葛均波,钱菊英,等.骨髓干细胞移植治疗心肌梗死的临床疗效[J].心脏杂志,2008;20(5):593-595.
[7] Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12): 1210-1221.
[8] Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113(10):1287-1294.
[9] 阮光萍,姚翔,刘菊芬,等.人脐带间充质干细胞的作用:细胞移植、免疫调节及充当基因治疗靶细胞[J].中国组织工程研究,2014,18(41):6714-6718.
[10] Leor J, Guetta E, Feinberg MS, et al. Human umbilical cord blood-derived CD133+ cells enhance function and repair of the infarcted myocardium. Stem Cells. 2006;24(3):772-780.
[11] Ma N, Ladilov Y, Moebius JM, et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells. Cardiovasc Res. 2006;71(1): 158-169.
[12] Sadat S, Gehmert S, Song YH, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun. 2007;363(3):674-679.
[13] Siepe M, Akhyari P, Lichtenberg A, et al. Stem cells used for cardiovascular tissue engineering. Eur J Cardiothorac Surg. 2008;34(2):242-247.
[14] Schächinger V, Aicher A, Döbert N, et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation. 2008; 118(14):1425-1432.
[15] Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg. 2007; 31(3):438-443.
[16] van den Akker F, Deddens JC, Doevendans PA, et al. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2013;1830(2):2449-2458.
[17] Henning RJ. Stem cells in cardiac repair. Future Cardiol. 2011;7(1):99-117.
[18] Chen Z, Li T, Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res. 2008;145(2):287-294.
[19] Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet. 2006;367(9509):456- 458.
[20] Kaneda K, Miyamae M, Sugioka S, et al. Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. Anesth Analg. 2008;106(1):9-16.
[21] Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56(1):127-136.
[22] Wong GT, Li R, Jiang LL, et al. Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010; 54(4):510-518.
[23] 刘鲲鹏,廖旭,薛富善,等.舒芬太尼的药理学和临床应用[J].药物临床与应用,2005,7(6):454-457.
[24] 谢丽萍,代志刚,王胜,等. 舒芬太尼预处理在大鼠肝缺血再灌注损伤中的作用及其与p38MAPK关系的研究[J].重庆医学,2014,43(23):3037-3039.
[25] 刘鲲鹏,孙海涛,薛富善,等.不同剂量舒芬太尼预处理对大鼠的延迟性心肌保护作用[J].中华麻醉学杂志,2009, 29(5):405-408.
[26] 李进,袁世荧,丰新民,等.舒芬太尼延迟预处理对兔心肌缺血再灌注损伤的影响[J].中麻醉学杂志,2009,29(8): 692-695.
[27] 孙海涛,薛富善,刘鲲鹏,等.COX-2和mito-KATP通道在舒芬太尼预处理对心肌缺血再灌注大鼠延迟性心肌保护中的作用[J].中华麻醉学杂志,2010,30(4):456-460.
[28] 李雅娇.人脐血间充质干细胞治疗急性心肌梗死的研究[J].中国民族民间医药,2013,22(11):106-107.
[29] 吴云,顾尔伟,方卫平,等. 舒芬太尼后处理对在体大鼠心肌缺血再灌注损伤的影响[J].安徽医科大学学报, 2011, 46(7): 652-655.
[30] 刘祥,景桂霞,白娟,等.舒芬太尼预处理对大鼠心肌缺血再灌注时PI3K/Akt的影响[J].南方医科大学学报, 2014, 34(3): 335-340.
[31] 王嘉,赵国庆,高明.舒芬太尼预处理对大鼠心肌缺血再灌注损伤的影响[J].中国实验诊断学,2012,16(7): 1162-1164.
[32] 朱健,王建刚,田首元,等.舒芬太尼后处理对大鼠心肌缺血再灌注损伤的影响及其与PI3K-Akt-eNOS的关系[J].中西医结合心脑血管病杂志,2014,12(11):1365-1367.
[33] 李军,秦建伟,梁永年,等.依达拉奉在联合瓣膜置换术中对心肌的保护作用[J].南京医科大学学报:自然科学版, 2006, 26(9): 849-851.
[34] 张启霞,秦玲.碟脉灵注射液对心肌缺血再灌注损伤大鼠心肌肌钙蛋白I、T的影响[J].中国老年学杂志,2010, 30(1):58-59.
[35] Collinson PO, Gaze DC. Biomarkers of cardiovascular damage. Med Princ Pract. 2007;16(4):247-261.
[36] 冬梅,侯春丽,常业恬,等.舒芬太尼预处理对缺血再灌注大鼠心肌梗死范围及心肌酶的影响[J].实用医学杂志, 2009, 25(15):2430-2433.
[37] 陈中青,张冬梅,贾绍斌. 舒芬太尼对大鼠心肌缺血再灌注室性心律失常的影响[J].中国心脏起搏与心电生理杂志,2009,23(3):247-249.
[38] 杨玲,梁红霞.舒芬太尼延迟性预处理对心肌缺血再灌注损伤及Caspase-3的影响[J].中华胸心血管外科杂志, 2010,26(4):269-272.
[39] Ruixing Y, Al-Ghazali R, Wenwu L, et al. Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. Scand J Clin Lab Invest. 2006;66(7):549-558.
[40] Vohra HA, Galiñanes M. Effect of the degree of ischaemic injury and reoxygenation time on the type of myocardial cell death in man: role of caspases. BMC Physiol. 2005;5:14. |